The Role of Dopaminergic Agents and the Dopamine Receptor in Treatment for CHF

Carey, Roberta B.; Jacob, Leonard

doi:10.1002/j.1552-4604.1989.tb03314.x

Cited by 11 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in intracellular calcium, which is a second messenger for the myosin–actin cross-bridge formation, will ultimately increase the contractile force. The inotropic characteristic of dopamine has been used in patients with advanced heart failure (Carey and Jacob, 1989). Consistent with this notion, dopamine increases myocardial muscle contraction in anesthetized fish (Figures 3 and 5).…”

Section: Discussionmentioning

confidence: 99%

A Comparative Study of Embedded and Anesthetized Zebrafish in vivo on Myocardiac Calcium Oscillation and Heart Muscle Contraction

Muntean¹,

Horvat²,

Behler³

et al. 2010

Front. Pharmacol.

View full text Add to dashboard Cite

The zebrafish (Danio rerio) has been used as a model for studying vertebrate development in the cardiovascular system. In order to monitor heart contraction and cytosolic calcium oscillations, fish were either embedded in methylcellulose or anesthetized with tricaine. Using high-resolution differential interference contrast and calcium imaging microscopy, we here show that dopamine and verapamil alter calcium signaling and muscle contraction in anesthetized zebrafish, but not in embedded zebrafish. In anesthetized fish, dopamine increases the amplitude of cytosolic calcium oscillation with a subsequent increase in heart contraction, whereas verapamil decreases the frequency of calcium oscillation and heart rate. Interestingly, verapamil also increases myocardial contraction. Our data further indicate that verapamil can increase myocardial calcium sensitivity in anesthetized fish. Taken together, our data reinforce in vivo cardiac responses to dopamine and verapamil. Furthermore, effects of dopamine and verapamil on myocardial calcium and contraction are greater in anesthetized than embedded fish. We suggest that while the zebrafish is an excellent model for a cardiovascular imaging study, the cardio-pharmacological profiles are very different between anesthetized and embedded fish.

show abstract

Section: Discussionmentioning

confidence: 99%

A Comparative Study of Embedded and Anesthetized Zebrafish in vivo on Myocardiac Calcium Oscillation and Heart Muscle Contraction

Muntean¹,

Horvat²,

Behler³

et al. 2010

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Intravenous administration of dopamine (the only approved route of administration) or the D1-like receptor agonist fenoldopam are positive inotropes that lead to rapid recovery in these acute conditions ( Doggrell, 2002 ; Feketeova et al, 2018 ; Zingales et al, 2021 ). Activation of both dopamine and adrenergic receptors is thought to be involved in the positive effects during sepsis ( Ruffolo et al, 1984 ; Carey and Jacob, 1989 ), although some studies find use of dopamine over a more specific adrenergic agonist may create a higher risk of side effects ( Pollard et al, 2015 ). High doses of dopamine can increase the risk of adverse effects in the treatment of sepsis ( Jentzer and Hollenberg, 2021 ), and a trial comparing the hemodynamic efficacy of dopamine to norepinephrine and dobutamine in elderly individuals with sepsis found that norepinephrine showed superior effects in improving hemodynamic stability and vascular elasticity and reducing inflammatory markers in the circulation ( Zhou, Cui et al, 2021 ).…”

Section: Regional and Disease-specific Effects Of Dopaminementioning

confidence: 99%

Dopamine, Immunity, and Disease

et al. 2022

View full text Add to dashboard Cite

The neurotransmitter dopamine is a key factor in central nervous system (CNS) function, regulating many processes including reward, movement, and cognition. Dopamine also regulates critical functions in peripheral organs, such as blood pressure, renal activity, and intestinal motility. Beyond these functions, a growing body of evidence indicates that dopamine is an important immunoregulatory factor. Most types of immune cells express dopamine receptors and other dopaminergic proteins, and many immune cells take up, produce, store, and/or release dopamine, suggesting that dopaminergic immunomodulation is important for immune function. Targeting these pathways could be a promising avenue for the treatment of inflammation and disease, but despite increasing research in this area, data on the specific effects of dopamine on many immune cells and disease processes remain inconsistent and poorly understood. Therefore, this review integrates the current knowledge of the role of dopamine in immune cell function and inflammatory signaling across systems. We also discuss the current understanding of dopaminergic regulation of immune signaling in the CNS and peripheral tissues, highlighting the role of dopaminergic immunomodulation in diseases such as Parkinson’s disease, several neuropsychiatric conditions, neurologic human immunodeficiency virus, inflammatory bowel disease, rheumatoid arthritis, and others. Careful consideration is given to the influence of experimental design on results, and we note a number of areas in need of further research. Overall, this review integrates our knowledge of dopaminergic immunology at the cellular, tissue, and disease level and prompts the development of therapeutics and strategies targeted toward ameliorating disease through dopaminergic regulation of immunity. Significance Statement Canonically, dopamine is recognized as a neurotransmitter involved in the regulation of movement, cognition, and reward. However, dopamine also acts as an immune modulator in the central nervous system and periphery. This review comprehensively assesses the current knowledge of dopaminergic immunomodulation and the role of dopamine in disease pathogenesis at the cellular and tissue level. This will provide broad access to this information across fields, identify areas in need of further investigation, and drive the development of dopaminergic therapeutic strategies.

show abstract

“…The underlying mechanisms include vasodilation, primarily in renal, mesenteric, coronary, and cerebral vascular beds, natriuresis, and diuresis (DA,-receptor-mediated) in addition to the inhibition of norepinephrine release from the sympathetic nerve terminals (DA2-receptor-mediated). Peripheral dopamine receptors are probably not downregulated in heart failure and selective dopaminergic agents have been suggested to be of value in the treatment for congestive heart failure (32). However, in isolated human ventricular papillary muscles obtained from patients with mitral valve disease, dopamine-induced positive inotropic responses are impaired (28).…”

Section: Dopamine Receptorsmentioning

confidence: 99%